Jubilant Life gets USFDA nod for generic anti-depressant tablets
Advertisement
New Delhi: Jubilant Life Sciences Ltd has received final approval from the US health regulator for its generic version of anti-depressant Paxil tablets.
The final approval for the abbreviated new drug application (ANDA) from the US Food and Drug Administration (USFDA) for Paroxetine tablets of Apotex is for strengths of 10 mg, 20 mg, 30 mg and 40 mg, the company said in a Bombay Stock Exchange (BSE) filing.
As on September 30, 2015, Jubilant Life Sciences had a total of 820 filings for formulations, of which 391 have been approved in various regions globally.
"These include 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.